Published in Z Rheumatol on April 01, 2014
Are there new approaches for diagnosis, therapy guidance and outcome prediction of sepsis? World J Exp Med (2015) 0.85
Humanized anti-interleukin-6 receptor antibody treatment of multicentric Castleman disease. Blood (2005) 4.29
A pilot randomized trial of a human anti-interleukin-6 receptor monoclonal antibody in active Crohn's disease. Gastroenterology (2004) 2.75
Rapid induction of remission in large vessel vasculitis by IL-6 blockade. A case series. Swiss Med Wkly (2011) 2.46
Improvement in Castleman's disease by humanized anti-interleukin-6 receptor antibody therapy. Blood (2000) 2.31
Tocilizumab in systemic lupus erythematosus: data on safety, preliminary efficacy, and impact on circulating plasma cells from an open-label phase I dosage-escalation study. Arthritis Rheum (2010) 1.86
Successful treatment of reactive arthritis with a humanized anti-interleukin-6 receptor antibody, tocilizumab. Arthritis Rheum (2009) 1.51
Comparison of the clinical utility of tocilizumab and anti-TNF therapy in AA amyloidosis complicating rheumatic diseases. Mod Rheumatol (2014) 1.08
The skin of patients with systemic sclerosis softened during the treatment with anti-IL-6 receptor antibody tocilizumab. Rheumatology (Oxford) (2010) 1.08
Successful use of a humanized anti-interleukin-6 receptor antibody, tocilizumab, to treat amyloid A amyloidosis complicating juvenile idiopathic arthritis. Arthritis Rheum (2006) 1.04
Role of interleukin-6 in a patient with tumor necrosis factor receptor-associated periodic syndrome: assessment of outcomes following treatment with the anti-interleukin-6 receptor monoclonal antibody tocilizumab. Arthritis Rheum (2011) 0.99
Tocilizumab ameliorates clinical symptoms in polymyalgia rheumatica. J Rheumatol (2010) 0.98
Outcomes of patients with systemic sclerosis-associated polyarthritis and myopathy treated with tocilizumab or abatacept: a EUSTAR observational study. Ann Rheum Dis (2012) 0.98
Sustained response to tocilizumab, anti-interleukin-6 receptor antibody, in two patients with refractory relapsing polychondritis. Rheumatology (Oxford) (2008) 0.97
A case of Behçet's disease treated with a humanized anti-interleukin-6 receptor antibody, tocilizumab. Mod Rheumatol (2011) 0.96
Benefit and a possible risk of tocilizumab therapy for adult-onset Still's disease accompanied by macrophage-activation syndrome. Mod Rheumatol (2010) 0.94
Anti-interleukin 6 receptor therapy as rescue treatment for giant cell arteritis. Ann Rheum Dis (2011) 0.93
Tocilizumab dramatically ameliorated life-threatening diarrhea due to secondary amyloidosis associated with rheumatoid arthritis. Clin Rheumatol (2009) 0.91
Excellent therapeutic effect of tocilizumab on intestinal amyloid a deposition secondary to active rheumatoid arthritis. Clin Rheumatol (2010) 0.90
Treatment of refractory adult-onset Still's disease with tocilizumab: report of two cases and review of the literature. Rheumatol Int (2011) 0.89
Therapeutic effect of tocilizumab on two patients with polymyositis. Rheumatology (Oxford) (2011) 0.88
A case of refractory adult-onset Still's disease successfully controlled with tocilizumab and a review of the literature. Clin Rheumatol (2010) 0.88
Tocilizumab improves systemic rheumatoid vasculitis with necrotizing crescentic glomerulonephritis. Mod Rheumatol (2014) 0.87
Mixed response to tocilizumab for ankylosing spondylitis. Ann Rheum Dis (2010) 0.86
Rapid improvement of AA amyloidosis with humanised anti-interleukin 6 receptor antibody treatment. Ann Rheum Dis (2009) 0.86
Immunotherapeutic implication of IL-6 blockade. Immunotherapy (2012) 0.83
A case report of a patient with refractory adult-onset Still's disease who was successfully treated with tocilizumab over 6 years. Mod Rheumatol (2008) 0.83
Treatment of a patient with remitting seronegative, symmetrical synovitis with pitting oedema with a humanized anti-interleukin-6 receptor antibody, tocilizumab. Rheumatology (Oxford) (2009) 0.75